1-3 of 3
Richard van Wijk
Close
Sort by
Journal Articles

Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease

Clinical Trials & Observations
Minke A. E. Rab, Celeste K. Kanne, Camille Boisson, Jennifer Bos, Brigitte A. van Oirschot, Maite E. Houwing, Céline Renoux, Marije Bartels, Anita W. Rijneveld, Erfan Nur, Marjon H. Cnossen, Philippe Joly, Elie Nader, Romain Fort, Philippe Connes, Richard van Wijk, Vivien A. Sheehan, Eduard J. van Beers
Journal: Blood Advances
Blood Adv (2024) 8 (2): 276–286.
https://doi.org/10.1182/bloodadvances.2023011013
Published: 2024
Includes: Supplemental data
Journal Articles

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study

Clinical Trials & Observations
Myrthe J. van Dijk, Minke A. E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J. M. Jans, Wouter W. van Solinge, Roger E. G. Schutgens, Richard van Wijk, Eduard J. van Beers
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7539–7550.
https://doi.org/10.1182/bloodadvances.2023011477
Published: 2023
Includes: Supplemental data
Journal Articles

Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia

Annelies. J. van Vuren, Michele F. Eisenga, Stephanie van Straaten, Andreas Glenthøj, Carlo A. J. M. Gaillard, Stephan J. L. Bakker, Martin H. de Borst, Richard van Wijk, Eduard J. van Beers
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1678–1682.
https://doi.org/10.1182/bloodadvances.2020001595
Published: 2020